A new therapy to prevent the
progression of COVID-19
The aim of the COVend Consortium is to deliver a new effective therapy against SARS-CoV-2 for the clinical management of the COVID-19 disease.
The COVend Consortium sets up to prevent COVID-19 progression to severe disease status by targeting endothelial dysfunction.
Some of the technologies involved in the process will be OMICs technologies for biomarker profiling, research on endothelial cell damage and AI for Data Analytics and modelling.
Having cured a patient with Ebola, it was clear to Prof. Zacharowski that FX06 could also be beneficial against COVID-19.
COVend involves partners from all over Europe, with a variety of clinical sites based in different European countries, enabling the delivery of FX06 as a promising candidate to prevent progression from mild & moderate to severe stages of COVID-19. Hear from some COVend partners and discover how COVend is making a difference today!
On the 13th of November, the consortium member of our partner institution UMCG, Clazinus Veijer, presented his poster “Lessons learned from model-based economic evaluations of COVID-19 treatments under pandemic circumstances: results from a systematic review ” at ISPOR Europe 2023. The poster highlighted results from a systematic review of various methodological characteristics of model-based economic evaluations of COVID-19 treatments.
Exciting research from COVend presented at the joint conference of the Société Française d’Immunologie & Deutsche Gesellschaft für Immunologie in Strasbourg!
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
FOR INQUIRIES, PLEASE SEND US AN EMAIL AT [email protected]
© accelopment Schweiz AG · [email protected] · ISO 9001 certified · Read our Privacy Policy
